Cargando…

Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells

INTRODUCTION: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target immune checkpoints that suppress immune cell activity. Low efficiency and high resistance are currently the main barriers to their clinical application. As a representative technology of targeted protein degradat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yu-Ying, Wang, An-Jin, Liu, Xue-Lian, Dai, Meng-Yuan, Cai, Hong-Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262918/ https://www.ncbi.nlm.nih.gov/pubmed/37325638 http://dx.doi.org/10.3389/fimmu.2023.1193222

Ejemplares similares

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells
por: Dai, Meng-Yuan, et al.
Publicado: (2022)

A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells
por: Shi, Yu-Ying, et al.
Publicado: (2023)

Specific MHC-I Peptides Are Induced Using PROTACs
por: Jensen, Stephanie M., et al.
Publicado: (2018)

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
por: Chen, Si, et al.
Publicado: (2022)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
por: Wang, Kun, et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors
por: Li, Song, et al.
Publicado: (2021)

Comparison of circular stapling, triangulating stapling and T-shape stapling for cervical anastomosis with minimally invasive esophagectomy
por: Tian, Yu, et al.
Publicado: (2020)

Peptide Stapling Applied to Antimicrobial Peptides
por: Lourenço, Ana Laura Pereira, et al.
Publicado: (2023)

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
por: Liu, Xuelian, et al.
Publicado: (2023)

Hydrocarbon Stapled Antimicrobial Peptides
por: Migoń, Dorian, et al.
Publicado: (2018)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Stapled Peptides Inhibitors: A New Window for Target Drug Discovery
por: Ali, Ameena M., et al.
Publicado: (2019)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer
por: Lu, Lu, et al.
Publicado: (2022)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
por: Rotman, Jossie, et al.
Publicado: (2020)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer
por: Mitra, Shreya, et al.
Publicado: (2017)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
por: Yin, Jianqiong, et al.
Publicado: (2022)

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
por: Gou, Miaomiao, et al.
Publicado: (2023)

Antiviral PROTACs: Opportunity borne with challenge
por: Liang, Jinsen, et al.
Publicado: (2023)

Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021)

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
por: Jin, Jinmei, et al.
Publicado: (2020)

C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients
por: Zhang, Yiyang, et al.
Publicado: (2022)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

Fish Granzyme A Shows a Greater Role Than Granzyme B in Fish Innate Cell-Mediated Cytotoxicity
por: Chaves-Pozo, Elena, et al.
Publicado: (2019)

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
por: Chen, Yu, et al.
Publicado: (2020)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2018)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
por: Ye, Wenling, et al.
Publicado: (2023)

The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
por: Tang, Yanyan, et al.
Publicado: (2020)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
por: Li, Butuo, et al.
Publicado: (2021)

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge
por: Li, Chen, et al.
Publicado: (2023)

Structural optimization of reversible dibromomaleimide peptide stapling
por: Lindsey‐Crosthwait, Ayanna, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Unexpected involvement of staple leads to redesign of selective bicyclic peptide inhibitor of Grb7
por: Gunzburg, Menachem J., et al.
Publicado: (2016)

A Stapled Peptide Mimic of the Pseudosubstrate Inhibitor PKI Inhibits Protein Kinase A
por: Manschwetus, Jascha T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0lqqdgm9k6qcle09nb0qkotjnk